Wednesday, August 23, 2023

Rapport Therapeutics Finds $150M In Series B

San Diego- and Boston-based Rapport Therapeutics has raised $150M in a Series B funding round, the company said this morning. According to the company, the funding was led by Cormorant Asset Management, and also included Fidelity Management & Research Company, Goldman Sachs Asset Management, Logos Capital, Perceptive Advisors, Sofinnova Investments, Surveyor Capital (a Citadel company), funds and accounts advised by T. Rowe Price Associates, Inc., plus its existing investors, which include Third Rock Ventures, ARCH Venture Partners and Johnson & Johnson Innovation. As part of the funding, it has added Raymond Kelleher of Cormorant Asset Management and James Healy of Sofinnova Investments to its board.